We are live on ! Find out more
ENVB icon

Enveric Biosciences
ENVB

14 hedge funds and large institutions have $2.72M invested in Enveric Biosciences in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

56% more funds holding

Funds holding: 9 → 14 (+5)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

20% less capital invested

Capital invested by funds: $3.42M → $2.72M (-$700K)

Holders
14
Holders Change
+5
Holders Change %
+55.56%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$214K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$85.7K
3
UBS Group
UBS Group
Switzerland
+$85.7K
4
Northern Trust
Northern Trust
Illinois
+$64.3K
5
PCM
Penserra Capital Management
California
+$64.3K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$300K
2
BlackRock
BlackRock
New York
-$129K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$65K
4
SSA
Schonfeld Strategic Advisors
New York
-$62K
5
EGM
Engineers Gate Manager
New York
-$21.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$1.21M -$129K -6 -10%
Vanguard Group
2
Vanguard Group
Pennsylvania
$432K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$235K +$85.7K +4 +57%
State Street
4
State Street
Massachusetts
$212K +$214K +10 New
UBS Group
5
UBS Group
Switzerland
$160K +$85.7K +4 +133%
VF
6
Virtu Financial
New York
$126K -$300K -14 -70%
Northern Trust
7
Northern Trust
Illinois
$87K +$64.3K +3 +300%
EGM
8
Engineers Gate Manager
New York
$72K -$21.4K -1 -25%
PCM
9
Penserra Capital Management
California
$52K +$64.3K +3 New
Creative Planning
10
Creative Planning
Kansas
$42K +$42.9K +2 New
Citadel Advisors
11
Citadel Advisors
Florida
$31K +$21.4K +1 New
S
12
SignatureFD
Georgia
$17K +$21.4K +1 New
Wells Fargo
13
Wells Fargo
California
$14K +$21.4K +1 New
TRCT
14
Tower Research Capital (TRC)
New York
$12K +$21.4K +1 New
FIA
15
FNY Investment Advisers
New York
$7K – – –
Osaic Holdings
16
Osaic Holdings
Arizona
$7K – – –
Bank of New York Mellon
17
Bank of New York Mellon
New York
– -$65K -2 Closed
SSA
18
Schonfeld Strategic Advisors
New York
– -$62K -2 Closed

ENVB Hedge Fund Activity: Q2 2021 in Review

14 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q2 2021, worth a combined $2.72M — down 20% from $3.42M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ENVB positions and 2 closed out — a net gain of 5 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was State Street, opening a new position worth an estimated $214K. The largest seller was Virtu Financial, cutting an estimated $300K.

  • 14 institutional investors held Enveric Biosciences (ENVB) as of Q2 2021, up from 9 in Q1 2021.
  • Funds reported $2.72M of Enveric Biosciences stock for Q2 2021, down 20% quarter-over-quarter.
  • 7 funds opened new Enveric Biosciences positions in Q2 2021 and 2 closed out, a net change of +5 holders.
  • The largest Enveric Biosciences buyer in Q2 2021 was State Street, an estimated $214K added.
  • The largest Enveric Biosciences seller in Q2 2021 was Virtu Financial, an estimated $300K sold.

Based on aggregated 13F filings for Q2 2021.